Improving treatment for severe lung and blood infections
Official title: Advancing Precision Medicine for ARDS and Sepsis
Funded at University of California, San Francisco · NIH-11034816 · Data updated 2026-11-12
This study is looking at how to better treat patients with serious lung and blood infections by figuring out their unique body responses, so doctors can give the right treatment to help them recover faster.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2032 |
| Funding year | 2025 |
| Award (this year) | $1,147,992 |
| NIH project number | 1R35HL177135-01 |
| Project ID | NIH-11034816 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are critically ill patients diagnosed with ARDS or sepsis, particularly those exhibiting hyperinflammatory or hypoinflammatory phenotypes.
✕Less likely to help
Patients with ARDS or sepsis who do not meet the criteria for the identified phenotypes may not benefit from this research.
What this research studies
This research focuses on understanding and treating acute respiratory distress syndrome (ARDS) and sepsis, two serious conditions that often lead to death in critically ill patients. By identifying different molecular phenotypes of these conditions, the research aims to tailor treatments based on individual patient characteristics, which could lead to better outcomes. The approach involves analyzing clinical data and plasma protein biomarkers to distinguish between patients who are hyperinflammatory and those who are hypoinflammatory, allowing for more effective therapeutic interventions. The goal is to develop a new paradigm in critical care medicine that enhances patient care and treatment efficacy.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for patients suffering from ARDS and sepsis.
How similar studies have gone: Previous research has shown promise in identifying molecular phenotypes in ARDS and sepsis, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Calfee, Carolyn — University of California, San Francisco
- Study coordinator: Calfee, Carolyn
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Innovative immune therapy with antibiotics to treat deadly inflammation in sepsis and ARDS in older adults
A new approach combines an antibiotic strategy with a special immune-based treatment to help older patients who have sepsis or ARDS from severe bacterial infection.
-
A new immune-blocking therapy plus antibiotics for severe sepsis and ARDS in older adults
This project is trying a treatment that restores a natural TREM1 blocker together with antibiotics to help older adults with life-threatening bacterial sepsis or ARDS.
-
Understanding ARDS, pneumonia, and sepsis: a big study to map how illness and recovery unfold
A large patient study at the University of Pennsylvania will follow adults with ARDS, pneumonia, or sepsis to learn how these conditions progress and recover over time.
-
Coordination and data sharing for ARDS, pneumonia, and sepsis research
A national collaborative effort to improve how researchers study ARDS, pneumonia, and sepsis by coordinating centers, data collection, and analyses.
-
Molecular profiling of ARDS, pneumonia, and sepsis in adults using advanced sequencing
A research team at four California hospitals will study adults with ARDS, pneumonia, or sepsis to identify molecular patterns in their illness using genetic sequencing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.